Plasma
Plasma donation referral for gay men remains open in EU’s blood revision
The revision of the EU's blood directive offers the chance to overhaul outdated restrictions that prevent those in same-sex relationships from becoming blood and plasma donors.
Without plasma treatment, life turns deeply insecure for Alpha-1 patients
As an Alpha-1 Antitrypsin Deficiency (AATD) patient, Frank Willersinn is dependent on a treatment with a plasma-derived medicine (PDMP) to make sure his body does not deteriorate.
Plasma donor compensation still an ‘open wound’ in EU’s blood directive revision
The debate over compensating plasma donations remains one of the more sensitive issues in the revision of the EU's blood, tissues and cells legislation.
US blood shortage crisis leaves EU patients vulnerable
The US is facing its worst blood and plasma shortage in more than a decade due to a combination of the COVID pandemic and bad weather conditions, which stakeholders have warned could have ripple effects across the pond. VideoPromoted content
The socioeconomic benefits of plasma-derived medicines
Every year more people across the EU are diagnosed with life-threatening conditions which can only be treated with plasma-derived medicines. VideoPromoted content
Facts about compensating plasma donors
The revision of the European Union Blood, Tissues and Cells (BTC) Legislation brings an opportunity to strengthen its legal framework to encourage new approaches that will increase the collection of plasma across Europe. VideoPromoted content
Strengthening the EU Blood Directive for patients who need plasma-derived medicines
The revision of the European Union Blood, Tissues and Cells (BTC) Legislation brings an opportunity to strengthen its legal framework to encourage new approaches that will increase the collection of plasma across Europe. VideoPromoted content
Europe needs to collect more plasma – Improving patient access to plasma-derived medicines
In the coming decade, it is expected that more European patients will need access to plasma-derived medicines.
The curious case of the English plasma supply
It’s not all about Brexit on the other side of the Channel as England is bracing to face up to another harsh challenge in the coming months: building an entire plasma supply chain from the scratch.OpinionPromoted content
Call for Action: Enhancing plasma collection through increased regulatory efficiency
The European Commission is currently revising the EU Blood, Tissue and Cells legislation, to take into account the most recent technological, scientific, epidemiological and societal developments.
New EU’s pharma rules: a game-changer for strategic autonomy on plasma?
Ensuring sufficient plasma collection in Europe remains a thorny issue but the forthcoming revision of the EU framework for pharmaceuticals offers the potential to turn the tide. InfographicPromoted content
Together toward a broader European plasma donation ecosystem
The unique aspects of human plasma need to be framed more precisely in the EU Blood Directive. The revision of the European Union Blood, Tissues and Cells Legislation brings an opportunity to strengthen this legal framework to encourage new approaches... InfographicPromoted content
Infographic: a health-economic assessment on immunoglobulin replacement therapy
This paper offers a health economic model to estimate the value of treatment with immunoglobulin replacement therapy (IgGRT) for CVID patients.
MEP: Clear EU definition of plasma would pave way for better awareness
Communication about the importance of plasma donations can be improved by focusing on a clear definition in the EU legislation, ensuring that more awareness is raised about the role it plays in producing life-saving medical products, a centre-right EU lawmaker told EURACTIV.
Commission: EU’s new blood directive to address dependency on US plasma
The ongoing revision of the European legislation on blood, tissues, and cells offers an opportunity to tackle the highly problematic dependency on plasma collected in the US for manufacturing plasma-derived medicinal products (PDMPs), according to an EU health official.
COVID-19 plasma therapy comes handy either way, EU Commission says
Even though the efficiency of plasma therapies against COVID-19 are not yet demonstrated, increasing Europe's blood collection capacity will contribute to address chronic shortages, the European Commission has said.
COVID-19 pandemic casts new light on plasma therapies
The use of COVID-19 convalescent plasma (CCP) as a therapeutic option, despite its ups and downs, has shown the European Union's renewed interest in plasma-derived medicinal products (PDMPs). InfographicPromoted content
Europe needs to collect more plasma
Plasma-derived medicinal products (PDMPs), derived from human plasma from healthy donors, are essential for around 300,000 European patients who rely on these therapies to treat a variety of rare, chronic, and potentially life-threatening conditions, which are often genetic in origin.... VideoPromoted content
